Taylor SA, et al. - In this multicentre trial (Streamline L trial) conducted in 16 hospitals in England, researchers performed a prospective comparison between the diagnostic accuracy and efficiency of whole-body magnetic resonance imaging (WB-MRI)-based staging pathways vs standard pathways in non-small-cell lung cancer patients. For WB-MRI and for standard pathways, the observed pathway sensitivity was 50% and 54%, respectively. There were no adverse events associated with imaging. Between the two pathways, no difference was found for specificity. For WB-MRI and for the standard pathway, the observed agreement with the multidisciplinary team's final treatment decision was 98% and 99%, respectively. Overall, the accuracy of WB-MRI staging pathways was similar to that of standard pathways, the former attenuated the staging time and costs.